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EDITORIAL
Erlotinib Accumulation in Brain Metastases from Non-small
Cell Lung Cancer
Visualization by Positron Emission Tomography in a Patient
Harboring a Mutation in the Epidermal Growth Factor Receptor
David J. Stewart, MD, and Jeremy J. Erasmus, MD
The Brief Report by Britta Weber et al. in this issue of the Journal of ThoracicOncology documents accumulation of erlotinib in brain metastases in a patient with
non-small cell lung cancer (NSCLC) imaged with positron emission tomography-com-
puted tomography (PET-CT) using a novel tracer [11C]-erlotinib.1 Dynamic PET imaging
showed accumulation of [11C]-erlotinib in the metastases, and this accumulation contin-
ued during the 60-minute study period, indicating binding to receptors on the tumor cells.
Fused PET-magnetic resonance imaging 3 weeks after the start of treatment showed
near-complete remission of brain and meningeal metastases. The marked improvement in
clinical performance status observed in this patient after administration of erlotinib, a
tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), has been
previously reported.2–4 Mutation analysis revealed that this patient’s tumor had a sensi-
tizing exon 19 deletion in the EGFR gene.
Metastases to the brain are common in patients with advanced NSCLC and, as
reported in this study, can be associated with substantial morbidity. However, earlier
detection and improved treatment options have improved survival. In this regard, the
report by Weber et al. confirms the potential value of systemic therapy in the treatment of
brain metastases and provides additional information that supplements recent reports
concerning clinical and objective responses of brain metastases in patients with NSCLC
after treatment with erlotinib or gefitinib. The authors indicate that the ability of these
drugs to accumulate in brain metastases has not been previously studied. This paucity of
information reflects the prevailing broader lack of understanding on drug concentrations
achieved in tumors within the brain and the role of the blood-brain barrier (the continuous,
nonfenestrated endothelial microvasculature of the brain parenchyma) in the resistance to
systemic therapy for intracerebral tumors.
Weber et al. state in their article that intravenous chemotherapy has limited
therapeutic effect in the treatment of brain metastases in patients with NSCLC due to poor
penetration of these drugs into brain tissue and cerebrospinal fluid. However, although
observations in the treatment of brain tumors have been used to infer that the blood-brain
barrier significantly decreases the efficacy of lipid insoluble chemotherapy drugs, the role
of the blood-brain barrier in the resistance of intracerebral tumors to chemotherapy is
unclear.5,6 In fact, the perception that the blood-brain barrier is a major factor in the
resistance to chemotherapy of brain metastases may be based in part on a bias in data
selection and interpretation.5,6
Limitations in the theory regarding the importance of the blood-brain barrier in brain
tumor chemotherapy are widely acknowledged. While there is general consensus that most
chemotherapy agents only attain comparatively low concentrations in the normal brain,
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many drugs attain therapeutic levels in brain tumors, compa-
rable to those in extracerebral tumors and normal tissues.7,8
For instance, the accumulation of cisplatin in brain tumors is
much higher than in the normal brain and can reach cytotoxic
levels.8 However, concentrations of chemotherapy agents that
occur in normal brain do not predict concentrations in brain
metastases. Drug cytotoxicity (or lack of it) is probably
generally a much more important factor in the efficacy of
therapy than is the limitation of drug uptake by the blood-
brain barrier. In fact, although the blood-brain barrier may
protect micrometastases that have not yet established their
own blood supply (and may thereby contribute to the devel-
opment of early posttherapy brain metastases), there is sub-
stantial clinical evidence that the blood-brain barrier has, at
most, a limited impact on the effectiveness of chemotherapy
on established brain metastases. For instance, low-molecular-
weight (MW) drugs such as temozolomide (MW  158) that
would be expected to penetrate normal brain tissue better than
high-molecular-weight drugs such as etoposide (MW  589)
or irinotecan (MW  587) are overall not more effective in
the treatment of brain metastases in patients with lung cancer.6
In addition, older studies suggested that adjuvant chemotherapy
of NSCLC with drugs such as cyclophosphamide, doxorubicin,
and cisplatin, which do not readily cross the intact blood-brain
barrier, reduced the risk of brain metastases comparable to the
reduction in risk of metastases to other organs.9 Furthermore,
efficacy of multiple systemic therapies for NSCLC brain metas-
tases has been documented.6 There is not a major difference in
survival after chemotherapy in patients with NSCLC who pres-
ent with brain metastases at the time of diagnosis compared with
those with metastases to other sites,10–13 particularly in patients
with multiple organ sites involved.14
The imaging of drug accumulation in brain metastases
by Weber et al. in a patient with NSCLC is interesting as to
date there have been relatively few human imaging studies on
the distribution of anticancer agents although both magnetic
resonance spectroscopy15,16 and imaging after administration
of radiolabeled agents17,18 have been used to a limited extent.
In addition to facilitating documentation of drug penetration
into brain tumors as reported by Weber et al., the ability to
image and visualize drug distribution may also help assess
other pharmacological questions. For example, magnetic res-
onance spectroscopy studies have shown that the efficacy of
5-fluorouracil in human gastrointestinal malignancies corre-
lated with intratumoral 5-fluorouracil half-life,15 and that this
half-life was increased by administration of methotrexate or
interferon.16 Imaging studies could also be used to test other
mechanisms of augmenting drug uptake into tumors. For
instance, due to the loss of autoregulation of blood flow in
tumors, increasing systemic blood pressure can preferentially
increase blood flow and drug delivery to tumors, with little
effect on normal tissues.19 Similarly, alterations of tumor
extracellular pH can also increase drug uptake into tumors. In
this regard, weak acids are taken up preferentially if extra-
cellular pH is acidic in response to a glucose load, while weak
bases are taken up preferentially if the extracellular pH is
alkalotic in response to a bicarbonate load.19 In addition,
preclinical studies of radiolabeled quinazoline have demon-
strated that it can be selectively visualized by PET imaging in
lung cancers with an EGFR L858R mutation that sensitizes
tumors to erlotinib and gefitinib.20 Conversely, this uptake is
blocked if the resistance-inducing T790M mutation is pres-
ent. Hence, in patients with lung cancer, imaging with this
compound could potentially predict sensitivity and resistance.
In summary, the authors have shown that erlotinib
accumulates in brain metastases and had a beneficial effect in
a patient with symptomatic brain metastases from NSCLC.
Importantly, the ability to image drug distribution could
become a useful tool in learning how to use these agents more
effectively. Furthermore, the current study is yet another
demonstration that systemic therapies can gain access to
intracerebral tumors despite limited access to the normal
central nervous system, and that drugs that are effective
against extracerebral disease may also provide worthwhile
palliation against brain metastases. NSCLC often responds
poorly to drug therapy, no matter what organ sites are
involved. However, it is essential to emphasize that the
perception that the blood-brain barrier precludes benefit from
systemic therapy is not borne out by published clinical
observations.5,6,21,22 Accordingly, patients with NSCLC and
brain metastases should be considered for inclusion in clinical
trials of new systemic agents as drug pharmacology, partic-
ularly as it pertains to drug uptake in the normal brain, may
not be an important determinant of treatment outcome.
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